GUJRATHI SHEILA — SEC insider filings

SEC reporting owner CIK 1575202. 20 insider filings on record with FilingPulse; latest filed 2026-10-27.

Transaction summary — filings shown

Covers all 20 filings on record, filed 2021-10-25 to 2026-10-27. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Ventyx Biosciences, Inc. (VTYX)Director111 leg · 130,000 sh · $300,5731 leg · 100,000 sh · $3,373,24019
Janux Therapeutics, Inc. (JANX)Director6——8
Bolt Biotherapeutics, Inc. (BOLT)Chief Strategy Officer, Director2——4
Processa Pharmaceuticals, Inc. (PCSA)Director1——2

Insider filings — GUJRATHI SHEILA

FiledFormIssuerReported transactionsSource
2026-10-273Bolt Biotherapeutics, Inc. (BOLT)Holdings only — no transactions reportedEDGAR
2026-10-274Bolt Biotherapeutics, Inc. (BOLT)Grant/award (A): 72,766 @ $0 · Grant/award (A): 13,055 @ $0 · Other (J): 2,763.83 (derivative) · Other (J): 495.87 (derivative)EDGAR
2026-07-304Processa Pharmaceuticals, Inc. (PCSA)Grant/award (A): 70,811.88 (derivative) · Grant/award (A): 12,311.28 (derivative)EDGAR
2026-03-044Ventyx Biosciences, Inc. (VTYX)Disposition to issuer (D): 130,000 · Disposition to issuer (D): 33,000 (derivative) · Disposition to issuer (D): 40,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · Disposition to issuer (D): 662,369 (derivative) · Disposition to issuer (D): 277,941 (derivative) · +2 moreEDGAR
2025-06-134Janux Therapeutics, Inc. (JANX)Grant/award (A): 3,750 @ $0 · Grant/award (A): 11,667 (derivative) @ $0EDGAR
2025-06-064Ventyx Biosciences, Inc. (VTYX)Grant/award (A): 40,000 (derivative) @ $0EDGAR
2024-12-264Ventyx Biosciences, Inc. (VTYX)Purchase (P): 130,000 @ $2.31EDGAR
2024-11-074Janux Therapeutics, Inc. (JANX)Other (J): 4,611 @ $0EDGAR
2024-06-284Janux Therapeutics, Inc. (JANX)Grant/award (A): 2,500 @ $0 · Grant/award (A): 8,350 (derivative) @ $0EDGAR
2024-06-074Ventyx Biosciences, Inc. (VTYX)Grant/award (A): 33,000 (derivative) @ $0EDGAR
2024-03-044Janux Therapeutics, Inc. (JANX)Other (J): 2,986 @ $0EDGAR
2024-01-234Ventyx Biosciences, Inc. (VTYX)Grant/award (A): 80,000 (derivative) @ $0EDGAR
2023-06-164Janux Therapeutics, Inc. (JANX)Grant/award (A): 12,500 (derivative) @ $0EDGAR
2023-06-124Ventyx Biosciences, Inc. (VTYX)Grant/award (A): 15,937 (derivative) @ $0EDGAR
2023-04-264/AVentyx Biosciences, Inc. (VTYX)Grant/award (A): 21,825 (derivative) @ $0EDGAR
2023-03-314Ventyx Biosciences, Inc. (VTYX)Option exercise (M): 100,000 @ $6.03 · Sale (S): 100,000 @ $33.73 · Option exercise (M): 100,000 (derivative) @ $0EDGAR
2022-06-164Janux Therapeutics, Inc. (JANX)Grant/award (A): 12,500 (derivative) @ $0EDGAR
2022-06-104Ventyx Biosciences, Inc. (VTYX)Grant/award (A): 13,301 (derivative) @ $0EDGAR
2021-12-034Ventyx Biosciences, Inc. (VTYX)Grant/award (A): 277,941 (derivative) @ $0EDGAR
2021-10-254Ventyx Biosciences, Inc. (VTYX)Conversion (C): 32,897 @ $0 · Conversion (C): 32,897 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2021-10-07 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1575202 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs